Moderna (NASDAQ:MRNA) has taken another step closer to making its dream of commercializing a coronavirus vaccine a reality. The company just released more detailed interim results from its phase 1 trial -- and they are enough for Moderna and investors to cheer about.
What's so encouraging about the results? And do they really bring Moderna close to victory? Let's take a look.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,